Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SNCA | P37840 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.48 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427804 | 1.00 | ACHE (0.50) | ACHESLC28A3KMT2ASNCAMEN1 | |
| SCHEMBL5427382 | 1.00 | ACHE (0.50) | ACHESLC28A3KMT2ASNCAMEN1 | |
| SCHEMBL17873961 | 1.00 | ACHE (0.50) | ACHESLC28A3KMT2ASNCAMEN1 | |
| SCHEMBL27932802 | 0.90 | SLC28A3 (0.49) | ACHESLC28A3SNCATYRGAA | |
| SCHEMBL5431937 | 0.87 | SNCA (0.57) | ACHESLC28A3KMT2ASNCAMEN1 | |
| SCHEMBL5428987 | 0.87 | SNCA (0.57) | ACHESLC28A3KMT2ASNCAMEN1 | |
| SCHEMBL5435886 | 0.87 | SNCA (0.57) | ACHESLC28A3KMT2ASNCAMEN1 | |
| SCHEMBL4636845 | 0.86 | TYR (0.59) | ACHESLC28A3SLC5A1SLC5A2TYR | |
| SCHEMBL8659653 | 0.82 | SLC5A2 (0.64) | SLC28A3KMT2AMEN1SLC5A1SLC5A2 | |
| SCHEMBL14164007 | 0.82 | SLC5A2 (0.64) | SLC28A3KMT2AMEN1SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173461-A1 | Glycoside prodrug of 5- aminosalicylic acid | NIPPON SHINYAKU CO., LTD. (JP) | 2007-07-26 | — | — | US | claimed |
| EP-1712555-A1 | PRODRUG COMPRISING 5-AMINOSALICYLATE GLYCOSIDE | Nippon Shinyaku Co., Ltd. (JP) | 2006-10-18 | — | — | EP | claimed |
| US-20070173461-A1 | Glycoside prodrug of 5- aminosalicylic acid | NIPPON SHINYAKU CO., LTD. (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173461-A1 | Glycoside prodrug of 5- aminosalicylic acid | NIPPON SHINYAKU CO., LTD. (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173461-A1 | Glycoside prodrug of 5- aminosalicylic acid | NIPPON SHINYAKU CO., LTD. (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1712555-A1 | PRODRUG COMPRISING 5-AMINOSALICYLATE GLYCOSIDE | Nippon Shinyaku Co., Ltd. (JP) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173461-A1 | Glycoside prodrug of 5- aminosalicylic acid | SI, FUT5, GALE | ACHE 1092/4885SLC28A3 2961/4885KMT2A 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.